First, anti-EGFR-mAb binds to EGFR and competitively inhibits its binding to endogenous ligands, blocking the transmission of crucial pathways and inhibiting the growth of tumor cells expressing EGFR.[27] Second, some studies have shown that some anti-EGFR-mAbs can induce an immune response and enhance the cytotoxic response to chemotherapy.[15,28,29] However, the advantages of combination therapy involving anti-EGFR mAb and platinum based chemotherapy have not been studied before. The gene discussed is EGFR; the disease is neoplasm.